Meisner Lara 4
4 · Viridian Therapeutics, Inc.\DE · Filed Jun 20, 2023
Insider Transaction Report
Form 4
Meisner Lara
General Counsel and Secretary
Transactions
- Exercise/Conversion
Common Stock
2023-06-15$23.03/sh+2,269$52,255→ 32,240 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-15−2,269→ 37,481 totalExercise: $23.03Exp: 2031-01-18→ Common Stock (2,269 underlying) - Sale
Common Stock
2023-06-15$28.02/sh−2,269$63,577→ 29,971 total - Exercise/Conversion
Common Stock
2023-06-16$23.03/sh+27$622→ 29,998 total - Sale
Common Stock
2023-06-16$28.35/sh−27$765→ 29,971 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-16−28→ 37,453 totalExercise: $23.03Exp: 2031-01-18→ Common Stock (28 underlying)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed pursuant to the Plan.
- [F3]The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.